Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Highlights on the treatment of Early TNBC: The KEYNOTE-522 study

#ESMO23: Breaking Science in Breast Cancer

Login to get immediate access to this content.

Login

Speaker: Peter Schmid, UK

#ESMO23: Breaking Science in Breast Cancer Video Series

Highlights on the treatment of Early TNBC: The KEYNOTE-522 study

Abstract discussed:

  • LBA18 - Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study

Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.

Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.

The study results covered, and speakers in this video series, have been selected exclusively by ESMO.

Published on 24 Oct 2023

Back to the Breaking Science in Breast Cancer Video Series

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.